S100A11 activates the pentose phosphate pathway to induce malignant biological behaviour of pancreatic ductal adenocarcinoma
Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most refractory malignancies and has a poor prognosis. In recent years, increasing evidence has shown that an imbalance of metabolism may contribute to unrestricted pancreatic tumour progression and that the pentose phosphate pathway (PP...
Main Authors: | Xue Zeng, Hong Guo, Zhuang Liu, Zilan Qin, Yuyang Cong, Naihan Ren, Yuxiang Zhang, Na Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2022-06-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-022-05004-3 |
Similar Items
-
S100A10, a novel biomarker in pancreatic ductal adenocarcinoma
by: Moamen Bydoun, et al.
Published: (2018-11-01) -
MicroRNAs as Indicators of Malignancy in Pancreatic Ductal Adenocarcinoma (PDAC) and Cystic Pancreatic Lesions
by: Christian Prinz, et al.
Published: (2022-08-01) -
Oral mycobiota and pancreatic ductal adenocarcinoma
by: Ailin Wei, et al.
Published: (2022-12-01) -
Ubiquitin signaling in pancreatic ductal adenocarcinoma
by: Shengnan Lv, et al.
Published: (2023-12-01) -
THE SUBTYPES OF PANCREATIC DUCTAL ADENOCARCINOMAS
by: Apeksha Kakkar, et al.
Published: (2016-12-01)